Tin tức & Cập nhật
Xem bài viết Khớp
Xem

COVID-19 vaccines safe for patients with rheumatic, musculoskeletal disease
Vaccines against SARS-CoV-2 has a safety profile that is similar in patients with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) and those with noninflammatory RMD (NI-RMD), according to a study. The vaccines are well tolerated with rare reports of I-RMD flare and serious adverse events.

Shorter flare duration best indicator of treatment success in gout
Patients with gout consider flare duration, flare frequency, and pain severity when thinking about treatment efficacy over time, according to a study. Of these factors, shorter flare duration is deemed to be the most common indicator of successful treatment.

Opioid medication linked to patients’ familiarity, perceptions of efficacy
Use of opioid among adults with knee and/or hip osteoarthritis (OA) often leads to being familiar with the treatment and believing that the medication is beneficial and low-risk, reveals a recent study.

Guselkumab safe, well tolerated in patients with psoriatic arthritis
Treatment with the monoclonal antibody targeting interleukin [IL]-23p19 guselkumab 100 mg, given either every 4 (Q4W) or 8 weeks (Q8W), is well tolerated in patients with psoriatic arthritis (PsA), with no new safety concerns through 1 year, according to pooled results of the DISCOVER-1 and DISCOVER-2 phase III trials.




